|View printer-friendly version|
"We are very pleased to advance our oral, alpha4beta7 integrin-specific antagonist peptide candidate, PTG-100, into this clinical proof-of-concept and dose optimization study," said
Patients will be randomized to one of four dose arms (150mg/300mg/900mg PTG-100 or placebo) for 12 weeks of once-daily oral dosing, followed by four weeks of safety follow-up. An interim futility analysis is expected to be performed in the second half of 2017, and if futility criteria are not met, one or two PTG-100 optimal doses will be selected for continued randomization of the remaining patients.
The primary efficacy endpoint of the study is clinical remission (as defined by rectal bleeding, stool frequency, and endoscopic subscores of the Mayo Score). Secondary endpoints include additional clinical and safety assessments, as well as pharmacokinetic, pharmacodynamic and other biomarker measurements of disease activity.
"PTG-100 is the most advanced asset to have emerged from our proprietary oral peptide technology platform that enables de novo discovery and optimization of novel peptides for protein:protein interaction (PPI) targets," said
Approximately 100 sites in
PTG-100 is a potential first-in-class product candidate that is being developed initially for the potential treatment of moderate-to-severe active ulcerative colitis. Alpha4beta7 integrin is considered to be one of the most gastrointestinal-specific biological targets for inflammatory bowel disease due to its binding to MAdCAM-1, a cell membrane protein that resides mostly in the gastrointestinal (GI) vasculature.
PTG-100, a potential first-in-class oral alpha4beta7 integrin antagonist is being developed initially for moderate-to-severe active ulcerative colitis. PTG-200, a potential first-in-class oral Interleukin-23 receptor antagonist is being developed initially for moderate-to-severe Crohn's disease and is currently in IND-enabling studies.
The company has a peptide technology platform that enables the discovery of oral and injectable peptides that can be utilized against a diverse set of targets and diseases including, but not confined to the GI. In addition to PTG-100 and PTG-200, the company is also engaged in the discovery and development of an injectable hepcidin mimetic, PTG-300, which is currently in IND-enabling studies. PTG-300 has potential utility for the treatment of iron overload disorders, such as beta-thalassemia and hereditary hemochromatosis, each of which may qualify PTG-300 for orphan drug designation.
Protagonist is headquartered in
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the potential for our programs, plans, timing and the availability of results of our clinical trials and the potential for eventual regulatory approval of our product candidates. In some cases you can identify these statements by forward-looking words such as "may," "will," "continue," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading "Risk Factors" contained in our quarterly report on Form 10-Q for the quarter ended
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/protagonist-therapeutics-initiates-phase-2b-study-of-oral-drug-candidate-ptg-100-in-ulcerative-colitis-300391589.html
Joan Kureczka, Kureczka/Martin Associates, Tel: +1 415-821-2413, Mobile: +1415-690-0210, email: Joan@Kureczka-martin.com OR For Investors, The Trout Group, Gitanjali Jain Ogawa, Tel: +1 646-378-2949, email: email@example.com